Mastering the Path: Developing Processes for Successful Clinical-Grade mRNA Manufacturing
REGISTER NOW
Broadcast Date: Wednesday, November 20, 2024Time: 8:00 am PT, 11:00 am ET, 17:00 CET
In this GEN webinar, we will aim to unlock the secrets behind the iterative process development that ensures the...
Baker Lab’s AI-Driven Antibody Cage Technology Unlocked as Archon Biosciences
Antibody Cages (AbCs) are a new class of biologic medicines that precisely orient antibodies in novel geometric configurations not found in nature. This new design space preserves the proven binding affinity properties of antibodies...
Space-based research uncovers key to cancer cell survival
In October, we think pink, and for a good reason-;one out of every eight women will be diagnosed with breast cancer in their lifetime, and each year, 2 million women are given this frightening...
Novel class of encrypted peptides offers hope against drug-resistant bacteria
In a significant advance against the growing threat of antibiotic-resistant bacteria, researchers have identified a novel class of antimicrobial agents known as encrypted peptides, which may expand the immune system's arsenal of tools to...
Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care
The 2024 National Foundation for Cancer Research (NFCR) Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship, co-hosted with the AIM-HI Accelerator Fund, convened the world's top experts across cancer research, biotech entrepreneurship,...
Cellevat3d Nanofiber Microcarrier Scaleup Demonstrated at Testa Center
Cellevate has reported the successful scaleup of its Cellevat3d® nanofiber microcarriers funded by Vinnova/STUNS Life Science. The study was performed at Testa Center in Uppsala, Sweden, in the 10-L Xcellerex XDR-10 single-use stirred tank...
Pseudomonas aeruginosa’s Tough Choice: Resist Antibiotics or Spread Infection
Pseudomonas aeruginosa is known to cause antibiotic-recalcitrant pneumonia and it is notoriously dangerous in people with lung diseases like cystic fibrosis, COPD, or bronchiectasis. P. aeruginosa forms biofilms—bacteria encased in a self-produced matrix that...
StockWatch: Sangamo Shares Surge on Shorter Pathway for Fabry Candidate
Shares of Sangamo Therapeutics (SGMO: NASDAQ) surged 69% this past week after the genetic medicines developer announced regulatory progress in its quest to develop its wholly owned gene therapy for Fabry disease—though one analyst...
Unraveling the survival strategies of Pseudomonas aeruginosa in lung infections
Imagine trying to settle into a new home while constantly being attacked. That's what the bacterium Pseudomonas aeruginosa faces when it infects the lungs, and it can't both spread and protect itself from antibiotics...
Prenatal Gene Therapy via LNPs Shows Promise in Model of Neurodevelopmental Disorder
The vehicles that deliver gene editing cargo to the body’s cells can be toxic, complicating gene therapies, particularly those addressed to brain cells of developing fetuses. Less toxic carriers, however, are being developed by...
